Details
- Autor(en) / Beteiligte
- Titel
- Risk factors for healthcare-associated extensively drug-resistant Acinetobacter baumannii infections: a case-control study
- Ist Teil von
- PloS one, 2014-01, Vol.9 (1), p.e85973-e85973
- Ort / Verlag
- United States: Public Library of Science
- Erscheinungsjahr
- 2014
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The emergence of extensively drug-resistant Acinetobacter baumannii (XDRAB) is a serious threat to hospitalized patients. From 2008 to 2010, surveillance detected 25 hospital-acquired infection (HAI) cases caused by XDRAB at a medical center in Taipei. The site of XDRAB infection was bloodstream (n = 8), urinary tract (n = 12), lower respiratory tract (n = 3), surgical site (n = 1), and cardiovascular (n = 1). The isolates were resistant to all currently available antibiotics except for colistin. The XDRAB isolates are genetically diverse, shown by pulsed-field gel electrophoresis, but 23 of 25 harbored class 1 integron with a 2.3-kb gene cassette. Most of these isolates carry OXA-23 (n = 21) and OXA-51-like carbapenemase genes (n = 25). To identify the risk factors, a case-control study was conducted. The 25 cases were compared with 100 controls randomly selected from hospitalized patients without XDRAB-HAIs, matched by the onset date, ward, and age, at a ratio of 1∶4. Prior use of imipenem, meropenem, piperacillin/tazobactam or fourth-generation cephalosporins (adjusted OR: 3.2, 95% CI: 1.03-10.2, P = 0.04) and >30 days bed-ridden (adjusted OR: 6.0, 95% CI: 1.3-27.6, P = 0.02) were found to be the independent risk factors for XDRAB-HAIs. These findings highlight that, even in the absence of clonal dissemination, XDRAB can emerge under the selective pressure of broad-spectrum antibiotics and causes subsequent HAIs in compromised hosts. An appropriate response to the XDRAB threat therefore should include a component of prudent use of broad-spectrum antibiotics active against gram-negative bacteria.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1932-6203eISSN: 1932-6203DOI: 10.1371/journal.pone.0085973Titel-ID: cdi_plos_journals_1490992784
- Format
- –
- Schlagworte
- Acinetobacter, Acinetobacter baumannii, Acinetobacter baumannii - drug effects, Acinetobacter baumannii - genetics, Acinetobacter baumannii - isolation & purification, Acinetobacter baumannii - physiology, Acinetobacter Infections - drug therapy, Acinetobacter Infections - epidemiology, Acinetobacter Infections - microbiology, Aged, Anti-Infective Agents - pharmacology, Anti-Infective Agents - therapeutic use, Antibacterial agents, Antibiotics, Antimicrobial agents, Bacteria, Bacterial Proteins - genetics, Bacterial Typing Techniques, beta-Lactamases - genetics, Biology, Carbapenemase, Case-Control Studies, Cephalosporins, Colistin, Cross infection, Cross Infection - drug therapy, Cross Infection - epidemiology, Cross Infection - microbiology, Delivery of Health Care, Deoxyribonucleic acid, Disease control, DNA, Drug resistance, Drug Resistance, Multiple, Bacterial - drug effects, Electrophoresis, Gel, Pulsed-Field, Epidemiology, Female, Gel electrophoresis, Genes, Genes, Bacterial - genetics, Gram-negative bacteria, Health aspects, Health care, Health care facilities, Hospital patients, Hospitals, Humans, Imipenem, Infections, Integrons - genetics, Intensive care, Internal medicine, Male, Medical centers, Medical laboratories, Medical research, Medicine, Medicine, Experimental, Meropenem, Methods, Microbial Sensitivity Tests, Multivariate Analysis, Nosocomial infections, Oxalic acid, Pathogens, Patients, Piperacillin, Preventive medicine, Pulsed-field gel electrophoresis, Respiratory tract, Risk analysis, Risk Factors, Risk management, Surgery, Surveillance, Taiwan - epidemiology, Tazobactam, Urinary tract